Aditxt Business Summary

Aditxt, Inc. (ADTX) is a commercial-stage biotechnology company specializing in immune monitoring and reprogramming technologies designed to optimize personalized health outcomes. The company generates revenue primarily through its AditxtScore™ platform, which provides high-complexity immune profiling services via its CLIA-certified laboratory, and through the commercialization of diagnostic products under its Pearsanta subsidiary. Its business model is increasingly defined by a "hub-and-spoke" strategy of strategic acquisitions and alliances, exemplified by its planned merger with Evofem Biosciences and the development of its Adimune™ therapeutic spoke for autoimmune diseases. Aditxt operates in a highly competitive and volatile micro-cap biotech sector, contending with direct rivals such as Onconetix (ONCO), GRI Bio (GRI), Carisma Therapeutics (CARM), and Scinai Immunotherapeutics (SCNI). Positioned as a high-risk, innovation-led player, the company is currently focused on regaining Nasdaq compliance and scaling its diagnostic revenue to offset significant operational burn rates. Aditxt was co-founded by Amro Albanna, Shahrokh Shabahang, and Courtland Mei, with a leadership team characterized by extensive experience in life science commercialization and serial entrepreneurship. CEO Amro Albanna brings a background of founding eight startups and leading multiple M&A and public-market transactions. Chief Innovation Officer Dr. Shahrokh Shabahang possesses over 20 years of experience in life science technology development, while CFO Thomas J. Farley provides critical oversight of the company’s complex capital-raising initiatives. The executive team is further supported by COO Rowena Albanna and Chief M&A Officer Corinne Pankovcin, who lead the company’s aggressive expansion and integration efforts. The Board of Directors includes notable independent members such as Brian Brady, a veteran investment director for major hospital systems, and Sylvia Hermina, an expert in corporate governance and shareholder relations. While institutional ownership remains concentrated among firms like StoneX Group and UBS Group AG, the leadership is currently steering the company through a proposed corporate rebranding to bitXbio, Inc. to align with its evolving focus on integrated health technologies.